CN115389756B - 一种预测房颤发生风险的检测试剂盒及其应用 - Google Patents
一种预测房颤发生风险的检测试剂盒及其应用 Download PDFInfo
- Publication number
- CN115389756B CN115389756B CN202211314441.XA CN202211314441A CN115389756B CN 115389756 B CN115389756 B CN 115389756B CN 202211314441 A CN202211314441 A CN 202211314441A CN 115389756 B CN115389756 B CN 115389756B
- Authority
- CN
- China
- Prior art keywords
- acid
- atrial fibrillation
- risk
- biomarker
- methionine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010003658 Atrial Fibrillation Diseases 0.000 title claims abstract description 63
- 238000001514 detection method Methods 0.000 title abstract description 13
- 239000000090 biomarker Substances 0.000 claims description 33
- ILUJQPXNXACGAN-UHFFFAOYSA-N O-methylsalicylic acid Chemical compound COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 claims description 32
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 32
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 24
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 24
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 24
- 229960003104 ornithine Drugs 0.000 claims description 24
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 23
- 229930182817 methionine Natural products 0.000 claims description 23
- 239000004475 Arginine Substances 0.000 claims description 22
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 22
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 22
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 22
- SXUXMRMBWZCMEN-UHFFFAOYSA-N 2'-O-methyl uridine Natural products COC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-UHFFFAOYSA-N 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- RFCQJGFZUQFYRF-UHFFFAOYSA-N 2'-O-Methylcytidine Natural products COC1C(O)C(CO)OC1N1C(=O)N=C(N)C=C1 RFCQJGFZUQFYRF-UHFFFAOYSA-N 0.000 claims description 18
- RFCQJGFZUQFYRF-ZOQUXTDFSA-N 2'-O-methylcytidine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 RFCQJGFZUQFYRF-ZOQUXTDFSA-N 0.000 claims description 18
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 18
- 229960000367 inositol Drugs 0.000 claims description 18
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 18
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 18
- CAHKINHBCWCHCF-JTQLQIEISA-N N-acetyl-L-tyrosine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-JTQLQIEISA-N 0.000 claims description 17
- -1 acetylglutamide Chemical compound 0.000 claims description 17
- 229960001682 n-acetyltyrosine Drugs 0.000 claims description 17
- XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 claims description 16
- 229940035893 uracil Drugs 0.000 claims description 16
- 229960003136 leucine Drugs 0.000 claims description 12
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 claims description 12
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 claims description 12
- 239000004395 L-leucine Substances 0.000 claims description 10
- 235000019454 L-leucine Nutrition 0.000 claims description 10
- 238000007675 cardiac surgery Methods 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 7
- 229960002920 sorbitol Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 238000004811 liquid chromatography Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 238000004949 mass spectrometry Methods 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 238000005259 measurement Methods 0.000 claims 1
- 239000000523 sample Substances 0.000 description 31
- 229960003121 arginine Drugs 0.000 description 20
- 239000002207 metabolite Substances 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 238000001356 surgical procedure Methods 0.000 description 10
- RFMMMVDNIPUKGG-YFKPBYRVSA-N N-acetyl-L-glutamic acid Chemical compound CC(=O)N[C@H](C(O)=O)CCC(O)=O RFMMMVDNIPUKGG-YFKPBYRVSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 4
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- ZTVZLYBCZNMWCF-UHFFFAOYSA-N homocystine Chemical compound [O-]C(=O)C([NH3+])CCSSCCC([NH3+])C([O-])=O ZTVZLYBCZNMWCF-UHFFFAOYSA-N 0.000 description 4
- HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 description 4
- 229950007031 palmidrol Drugs 0.000 description 4
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 description 4
- WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 description 4
- 239000013062 quality control Sample Substances 0.000 description 4
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- MPCAJMNYNOGXPB-SLPGGIOYSA-N 1,5-anhydro-D-glucitol Chemical compound OC[C@H]1OC[C@H](O)[C@@H](O)[C@@H]1O MPCAJMNYNOGXPB-SLPGGIOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- SLEHROROQDYRAW-KQYNXXCUSA-N N(2)-methylguanosine Chemical compound C1=NC=2C(=O)NC(NC)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O SLEHROROQDYRAW-KQYNXXCUSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 3
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 3
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 3
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- CCVYRRGZDBSHFU-UHFFFAOYSA-N (2-hydroxyphenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1O CCVYRRGZDBSHFU-UHFFFAOYSA-N 0.000 description 2
- GRYSXUXXBDSYRT-WOUKDFQISA-N (2r,3r,4r,5r)-2-(hydroxymethyl)-4-methoxy-5-[6-(methylamino)purin-9-yl]oxolan-3-ol Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1OC GRYSXUXXBDSYRT-WOUKDFQISA-N 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 2
- QUNWUDVFRNGTCO-UHFFFAOYSA-N 1,7-dimethylxanthine Chemical compound N1C(=O)N(C)C(=O)C2=C1N=CN2C QUNWUDVFRNGTCO-UHFFFAOYSA-N 0.000 description 2
- HPZMWTNATZPBIH-UHFFFAOYSA-N 1-methyladenine Chemical compound CN1C=NC2=NC=NC2=C1N HPZMWTNATZPBIH-UHFFFAOYSA-N 0.000 description 2
- CQSLTKIXAJTQGA-FLIBITNWSA-N 12,13-DiHOME Chemical compound CCCCCC(O)C(O)C\C=C/CCCCCCCC(O)=O CQSLTKIXAJTQGA-FLIBITNWSA-N 0.000 description 2
- SXUXMRMBWZCMEN-ZOQUXTDFSA-N 2'-O-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-ZOQUXTDFSA-N 0.000 description 2
- HYNQTSZBTIOFKH-UHFFFAOYSA-N 2-Amino-5-hydroxybenzoic acid Chemical compound NC1=CC=C(O)C=C1C(O)=O HYNQTSZBTIOFKH-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- ANOUKFYBOAKOIR-UHFFFAOYSA-N 3,4-dimethoxyphenylethylamine Chemical compound COC1=CC=C(CCN)C=C1OC ANOUKFYBOAKOIR-UHFFFAOYSA-N 0.000 description 2
- CJBDUOMQLFKVQC-UHFFFAOYSA-N 3-(2-hydroxyphenyl)propanoic acid Chemical compound OC(=O)CCC1=CC=CC=C1O CJBDUOMQLFKVQC-UHFFFAOYSA-N 0.000 description 2
- FSASIHFSFGAIJM-UHFFFAOYSA-N 3-methyladenine Chemical compound CN1C=NC(N)=C2N=CN=C12 FSASIHFSFGAIJM-UHFFFAOYSA-N 0.000 description 2
- LTFHNKUKQYVHDX-UHFFFAOYSA-N 4-hydroxy-3-methylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1O LTFHNKUKQYVHDX-UHFFFAOYSA-N 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- NRPFNQUDKRYCNX-UHFFFAOYSA-N 4-methoxyphenylacetic acid Chemical compound COC1=CC=C(CC(O)=O)C=C1 NRPFNQUDKRYCNX-UHFFFAOYSA-N 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 2
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 description 2
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 2
- JTEJPPKMYBDEMY-UHFFFAOYSA-N 5-methoxytryptamine Chemical compound COC1=CC=C2NC=C(CCN)C2=C1 JTEJPPKMYBDEMY-UHFFFAOYSA-N 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- XIGSAGMEBXLVJJ-YFKPBYRVSA-N L-homocitrulline Chemical compound NC(=O)NCCCC[C@H]([NH3+])C([O-])=O XIGSAGMEBXLVJJ-YFKPBYRVSA-N 0.000 description 2
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 2
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- SFIHQZFZMWZOJV-UHFFFAOYSA-N Linolsaeure-amid Natural products CCCCCC=CCC=CCCCCCCCC(N)=O SFIHQZFZMWZOJV-UHFFFAOYSA-N 0.000 description 2
- BVIAOQMSVZHOJM-UHFFFAOYSA-N N(6),N(6)-dimethyladenine Chemical compound CN(C)C1=NC=NC2=C1N=CN2 BVIAOQMSVZHOJM-UHFFFAOYSA-N 0.000 description 2
- DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 description 2
- SNEIUMQYRCDYCH-LURJTMIESA-N N(alpha)-acetyl-L-arginine Chemical compound CC(=O)N[C@H](C(O)=O)CCCNC(N)=N SNEIUMQYRCDYCH-LURJTMIESA-N 0.000 description 2
- NCIKQJBVUNUXLW-UHFFFAOYSA-N N-methyltryptamine Chemical compound C1=CC=C2C(CCNC)=CNC2=C1 NCIKQJBVUNUXLW-UHFFFAOYSA-N 0.000 description 2
- RFCVXVPWSPOMFJ-STQMWFEESA-N Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 RFCVXVPWSPOMFJ-STQMWFEESA-N 0.000 description 2
- PYOHODCEOHCZBM-RYUDHWBXSA-N Phe-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 PYOHODCEOHCZBM-RYUDHWBXSA-N 0.000 description 2
- IEHDJWSAXBGJIP-RYUDHWBXSA-N Phe-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])CC1=CC=CC=C1 IEHDJWSAXBGJIP-RYUDHWBXSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 229930185560 Pseudouridine Natural products 0.000 description 2
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 2
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- FPUGCISOLXNPPC-IOSLPCCCSA-N cordysinin B Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 FPUGCISOLXNPPC-IOSLPCCCSA-N 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 2
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- JTEDVYBZBROSJT-UHFFFAOYSA-N indole-3-butyric acid Chemical compound C1=CC=C2C(CCCC(=O)O)=CNC2=C1 JTEDVYBZBROSJT-UHFFFAOYSA-N 0.000 description 2
- OLNJUISKUQQNIM-UHFFFAOYSA-N indole-3-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CNC2=C1 OLNJUISKUQQNIM-UHFFFAOYSA-N 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 description 2
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 2
- SFIHQZFZMWZOJV-HZJYTTRNSA-N linoleamide Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(N)=O SFIHQZFZMWZOJV-HZJYTTRNSA-N 0.000 description 2
- KVWWIYGFBYDJQC-UHFFFAOYSA-N methyl dihydrojasmonate Chemical compound CCCCCC1C(CC(=O)OC)CCC1=O KVWWIYGFBYDJQC-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- BNJOQKFENDDGSC-UHFFFAOYSA-N octadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCCC(O)=O BNJOQKFENDDGSC-UHFFFAOYSA-N 0.000 description 2
- ZMHLUFWWWPBTIU-UHFFFAOYSA-N p-hydroxyhippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=C(O)C=C1 ZMHLUFWWWPBTIU-UHFFFAOYSA-N 0.000 description 2
- LPNBBFKOUUSUDB-UHFFFAOYSA-N p-toluic acid Chemical compound CC1=CC=C(C(O)=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-N 0.000 description 2
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 2
- UTYVDVLMYQPLQB-UHFFFAOYSA-N phenylacetylglycine Chemical compound OC(=O)CNC(=O)CC1=CC=CC=C1 UTYVDVLMYQPLQB-UHFFFAOYSA-N 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 108010084572 phenylalanyl-valine Proteins 0.000 description 2
- 108010073101 phenylalanylleucine Proteins 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 2
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 2
- 229940075559 piperine Drugs 0.000 description 2
- 235000019100 piperine Nutrition 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- DOYOPBSXEIZLRE-UHFFFAOYSA-N pyrrole-3-carboxylic acid Natural products OC(=O)C=1C=CNC=1 DOYOPBSXEIZLRE-UHFFFAOYSA-N 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940063673 spermidine Drugs 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- BHTRKEVKTKCXOH-AYSJQVDDSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-AYSJQVDDSA-N 0.000 description 2
- 229940034208 thyroxine Drugs 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- MBBOMCVGYCRMEA-UHFFFAOYSA-N tryptophol Chemical compound C1=CC=C2C(CCO)=CNC2=C1 MBBOMCVGYCRMEA-UHFFFAOYSA-N 0.000 description 2
- 238000007473 univariate analysis Methods 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- JYVXNLLUYHCIIH-UHFFFAOYSA-N (+/-)-mevalonolactone Natural products CC1(O)CCOC(=O)C1 JYVXNLLUYHCIIH-UHFFFAOYSA-N 0.000 description 1
- GDTXICBNEOEPAZ-FPLPWBNLSA-N (10Z)-heptadecenoic acid Chemical compound CCCCCC\C=C/CCCCCCCCC(O)=O GDTXICBNEOEPAZ-FPLPWBNLSA-N 0.000 description 1
- 239000001414 (2E)-2-(phenylmethylidene)octanal Substances 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- ZHSOTLOTTDYIIK-ZDUSSCGKSA-N (2S)-2-amino-3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C=C1 ZHSOTLOTTDYIIK-ZDUSSCGKSA-N 0.000 description 1
- IXOXBSCIXZEQEQ-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O IXOXBSCIXZEQEQ-KQYNXXCUSA-N 0.000 description 1
- PIXFHVWJOVNKQK-UHFFFAOYSA-N (3alpha,5alpha,11alpha)-3,11-Dihydroxyandrostan-17-one Natural products C1C(O)CCC2(C)C3C(O)CC(C)(C(CC4)=O)C4C3CCC21 PIXFHVWJOVNKQK-UHFFFAOYSA-N 0.000 description 1
- DKPMWHFRUGMUKF-UHFFFAOYSA-N (3alpha,5alpha,6alpha,7alpha)-3,6,7-Trihydroxycholan-24-oic acid Natural products OC1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DKPMWHFRUGMUKF-UHFFFAOYSA-N 0.000 description 1
- DXOCDBGWDZAYRQ-UHFFFAOYSA-N (3alpha,5beta)-3-Hydroxy-7-oxocholan-24 -oic acid Natural products C1CC(O)CC2CC(=O)C3C4CCC(C(CCC(O)=O)C)C4(C)CCC3C21C DXOCDBGWDZAYRQ-UHFFFAOYSA-N 0.000 description 1
- AUTOLBMXDDTRRT-JGVFFNPUSA-N (4R,5S)-dethiobiotin Chemical compound C[C@@H]1NC(=O)N[C@@H]1CCCCCC(O)=O AUTOLBMXDDTRRT-JGVFFNPUSA-N 0.000 description 1
- PLVPPLCLBIEYEA-AATRIKPKSA-N (E)-3-(indol-3-yl)acrylic acid Chemical compound C1=CC=C2C(/C=C/C(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-AATRIKPKSA-N 0.000 description 1
- IHCPDBBYTYJYIL-QVDQXJPCSA-N (R)-2-methylbutyrylcarnitine Chemical compound CCC(C)C(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IHCPDBBYTYJYIL-QVDQXJPCSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- QHGUCRYDKWKLMG-QMMMGPOBSA-N (R)-octopamine Chemical compound NC[C@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-QMMMGPOBSA-N 0.000 description 1
- LVRFTAZAXQPQHI-YFKPBYRVSA-N (S)-2-hydroxy-4-methylpentanoic acid Chemical compound CC(C)C[C@H](O)C(O)=O LVRFTAZAXQPQHI-YFKPBYRVSA-N 0.000 description 1
- IJBFSOLHRKELLR-BQYQJAHWSA-N (e)-dodec-5-enoic acid Chemical compound CCCCCC\C=C\CCCC(O)=O IJBFSOLHRKELLR-BQYQJAHWSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- OTSBKHHWSQYEHK-UHFFFAOYSA-N 1,3-dimethyluric acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(=O)N2 OTSBKHHWSQYEHK-UHFFFAOYSA-N 0.000 description 1
- JOYGXTIHTHBSOA-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-thiophen-2-ylprop-2-en-1-one Chemical compound C1=CC(Cl)=CC=C1C(=O)C=CC1=CC=CS1 JOYGXTIHTHBSOA-UHFFFAOYSA-N 0.000 description 1
- UTQUILVPBZEHTK-ZOQUXTDFSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3-methylpyrimidine-2,4-dione Chemical compound O=C1N(C)C(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UTQUILVPBZEHTK-ZOQUXTDFSA-N 0.000 description 1
- SGKGZYGMLGVQHP-ZOQUXTDFSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-methylpyrimidine-2,4-dione Chemical compound CC1=CC(=O)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SGKGZYGMLGVQHP-ZOQUXTDFSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- SATCOUWSAZBIJO-UHFFFAOYSA-N 1-methyladenine Natural products N=C1N(C)C=NC2=C1NC=N2 SATCOUWSAZBIJO-UHFFFAOYSA-N 0.000 description 1
- GFYLSDSUCHVORB-IOSLPCCCSA-N 1-methyladenosine Chemical compound C1=NC=2C(=N)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O GFYLSDSUCHVORB-IOSLPCCCSA-N 0.000 description 1
- UTAIYTHAJQNQDW-KQYNXXCUSA-N 1-methylguanosine Chemical compound C1=NC=2C(=O)N(C)C(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UTAIYTHAJQNQDW-KQYNXXCUSA-N 0.000 description 1
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
- CVNYHSDFZXHMMJ-UHFFFAOYSA-N 12-keto-lithocholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(=O)C2 CVNYHSDFZXHMMJ-UHFFFAOYSA-N 0.000 description 1
- CVNYHSDFZXHMMJ-VPUMZWJWSA-N 12-ketolithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)C(=O)C1 CVNYHSDFZXHMMJ-VPUMZWJWSA-N 0.000 description 1
- WPOCIZJTELRQMF-UHFFFAOYSA-N 16alpha-Hydroxyestrone Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)=O)C4C3CCC2=C1 WPOCIZJTELRQMF-UHFFFAOYSA-N 0.000 description 1
- WPOCIZJTELRQMF-QFXBJFAPSA-N 16alpha-hydroxyestrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C([C@H](O)C4)=O)[C@@H]4[C@@H]3CCC2=C1 WPOCIZJTELRQMF-QFXBJFAPSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
- FPUGCISOLXNPPC-UHFFFAOYSA-N 2'-O-Methyladenosine Natural products COC1C(O)C(CO)OC1N1C2=NC=NC(N)=C2N=C1 FPUGCISOLXNPPC-UHFFFAOYSA-N 0.000 description 1
- OVYNGSFVYRPRCG-UHFFFAOYSA-N 2'-O-Methylguanosine Natural products COC1C(O)C(CO)OC1N1C(NC(N)=NC2=O)=C2N=C1 OVYNGSFVYRPRCG-UHFFFAOYSA-N 0.000 description 1
- OVYNGSFVYRPRCG-KQYNXXCUSA-N 2'-O-methylguanosine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=C(N)NC2=O)=C2N=C1 OVYNGSFVYRPRCG-KQYNXXCUSA-N 0.000 description 1
- HPHXOIULGYVAKW-IOSLPCCCSA-N 2'-O-methylinosine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 HPHXOIULGYVAKW-IOSLPCCCSA-N 0.000 description 1
- HPHXOIULGYVAKW-UHFFFAOYSA-N 2'-O-methylinosine Natural products COC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 HPHXOIULGYVAKW-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- YKBGVTZYEHREMT-UHFFFAOYSA-N 2'-deoxyguanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(CO)O1 YKBGVTZYEHREMT-UHFFFAOYSA-N 0.000 description 1
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- JLLBPEUXSDBMIZ-UHFFFAOYSA-N 2,5-dibromobenzene-1,4-dicarbonitrile Chemical compound BrC1=CC(C#N)=C(Br)C=C1C#N JLLBPEUXSDBMIZ-UHFFFAOYSA-N 0.000 description 1
- DWLVFWDCSFTDOD-UHFFFAOYSA-N 2-(1h-indol-3-yl)-2-oxoacetic acid Chemical compound C1=CC=C2C(C(=O)C(=O)O)=CNC2=C1 DWLVFWDCSFTDOD-UHFFFAOYSA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- WHEUWNKSCXYKBU-UHFFFAOYSA-N 2-Methoxyestron Natural products C12CCC3(C)C(=O)CCC3C2CCC2=C1C=C(OC)C(O)=C2 WHEUWNKSCXYKBU-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-CBPJZXOFSA-N 2-amino-2-deoxy-D-mannopyranose Chemical compound N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-CBPJZXOFSA-N 0.000 description 1
- AKVBCGQVQXPRLD-UHFFFAOYSA-N 2-aminooctanoic acid Chemical compound CCCCCCC(N)C(O)=O AKVBCGQVQXPRLD-UHFFFAOYSA-N 0.000 description 1
- SWINWPBPEKHUOD-UHFFFAOYSA-N 2-hydroxyestron Natural products OC1=C(O)C=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 SWINWPBPEKHUOD-UHFFFAOYSA-N 0.000 description 1
- SWINWPBPEKHUOD-JPVZDGGYSA-N 2-hydroxyestrone Chemical compound OC1=C(O)C=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 SWINWPBPEKHUOD-JPVZDGGYSA-N 0.000 description 1
- WHEUWNKSCXYKBU-QPWUGHHJSA-N 2-methoxyestrone Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 WHEUWNKSCXYKBU-QPWUGHHJSA-N 0.000 description 1
- RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 description 1
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 1
- JVGVDSSUAVXRDY-UHFFFAOYSA-N 3-(4-hydroxyphenyl)lactic acid Chemical compound OC(=O)C(O)CC1=CC=C(O)C=C1 JVGVDSSUAVXRDY-UHFFFAOYSA-N 0.000 description 1
- XGILAAMKEQUXLS-UHFFFAOYSA-N 3-(indol-3-yl)lactic acid Chemical compound C1=CC=C2C(CC(O)C(O)=O)=CNC2=C1 XGILAAMKEQUXLS-UHFFFAOYSA-N 0.000 description 1
- IQGMRVWUTCYCST-UHFFFAOYSA-N 3-Aminosalicylic acid Chemical compound NC1=CC=CC(C(O)=O)=C1O IQGMRVWUTCYCST-UHFFFAOYSA-N 0.000 description 1
- UTQUILVPBZEHTK-UHFFFAOYSA-N 3-Methyluridine Natural products O=C1N(C)C(=O)C=CN1C1C(O)C(O)C(CO)O1 UTQUILVPBZEHTK-UHFFFAOYSA-N 0.000 description 1
- ACWBBAGYTKWBCD-ZETCQYMHSA-N 3-chloro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(Cl)=C1 ACWBBAGYTKWBCD-ZETCQYMHSA-N 0.000 description 1
- XDELKSRGBLWMBA-UHFFFAOYSA-N 3-iodopyridine Chemical compound IC1=CC=CN=C1 XDELKSRGBLWMBA-UHFFFAOYSA-N 0.000 description 1
- SXOPCLUOUFQBJV-UHFFFAOYSA-N 3-methoxyanthranilic acid Chemical compound COC1=CC=CC(C(O)=O)=C1N SXOPCLUOUFQBJV-UHFFFAOYSA-N 0.000 description 1
- DIVQKHQLANKJQO-UHFFFAOYSA-N 3-methoxytyramine Chemical compound COC1=CC(CCN)=CC=C1O DIVQKHQLANKJQO-UHFFFAOYSA-N 0.000 description 1
- JBAYRTVUCPJTBZ-UHFFFAOYSA-N 3-methyl-1h-indol-2-ol Chemical compound C1=CC=C2C(C)=C(O)NC2=C1 JBAYRTVUCPJTBZ-UHFFFAOYSA-N 0.000 description 1
- FBTSQILOGYXGMD-LURJTMIESA-N 3-nitro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 description 1
- PIXFHVWJOVNKQK-PTXZMSDUSA-N 3alpha,11beta-Dihydroxy-5alpha-androstane-17-one Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 PIXFHVWJOVNKQK-PTXZMSDUSA-N 0.000 description 1
- QGXBDMJGAMFCBF-BNSUEQOYSA-N 3alpha-hydroxy-5beta-androstan-17-one Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@@H]21 QGXBDMJGAMFCBF-BNSUEQOYSA-N 0.000 description 1
- KXGVEGMKQFWNSR-OFYXWCICSA-N 3beta,12alpha-dihydroxy-5beta-cholan-24-oic acid Chemical compound C([C@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-OFYXWCICSA-N 0.000 description 1
- AURFZBICLPNKBZ-FZCSVUEKSA-N 3beta-hydroxy-5alpha-pregnan-20-one Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-FZCSVUEKSA-N 0.000 description 1
- ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 description 1
- UZTFMUBKZQVKLK-UHFFFAOYSA-N 4-acetamidobutanoic acid Chemical compound CC(=O)NCCCC(O)=O UZTFMUBKZQVKLK-UHFFFAOYSA-N 0.000 description 1
- YBBDRHCNZBVLGT-FDDDBJFASA-N 4-amino-1-[(2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-2-oxopyrimidine-5-carbaldehyde Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C(C=O)=C1 YBBDRHCNZBVLGT-FDDDBJFASA-N 0.000 description 1
- OCMSXKMNYAHJMU-JXOAFFINSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidine-5-carbaldehyde Chemical compound C1=C(C=O)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 OCMSXKMNYAHJMU-JXOAFFINSA-N 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
- PUEXVLNGOBYUEW-BFDPJXHCSA-N 4-methoxyestrone Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC[C@H]3[C@@H]1CCC1=C2C=CC(O)=C1OC PUEXVLNGOBYUEW-BFDPJXHCSA-N 0.000 description 1
- TXXYYOUBDOAQDT-UHFFFAOYSA-N 4-nitro-1-(phenylmethoxymethyl)imidazole Chemical compound C1=NC([N+](=O)[O-])=CN1COCC1=CC=CC=C1 TXXYYOUBDOAQDT-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 1
- XGYIMTFOTBMPFP-KQYNXXCUSA-N 5'-deoxyadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 XGYIMTFOTBMPFP-KQYNXXCUSA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- IPRQAJTUSRLECG-UHFFFAOYSA-N 5-[6-(dimethylamino)purin-9-yl]-2-(hydroxymethyl)-4-methoxyoxolan-3-ol Chemical compound COC1C(O)C(CO)OC1N1C2=NC=NC(N(C)C)=C2N=C1 IPRQAJTUSRLECG-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- HLZXTFWTDIBXDF-PNHWDRBUSA-N 5-methoxycarbonylmethyl-2-thiouridine Chemical compound S=C1NC(=O)C(CC(=O)OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HLZXTFWTDIBXDF-PNHWDRBUSA-N 0.000 description 1
- YIZYCHKPHCPKHZ-PNHWDRBUSA-N 5-methoxycarbonylmethyluridine Chemical compound O=C1NC(=O)C(CC(=O)OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 YIZYCHKPHCPKHZ-PNHWDRBUSA-N 0.000 description 1
- COCNDHOPIHDTHK-UHFFFAOYSA-N 5-methoxyindole-3-acetic acid Chemical compound COC1=CC=C2NC=C(CC(O)=O)C2=C1 COCNDHOPIHDTHK-UHFFFAOYSA-N 0.000 description 1
- 229940097276 5-methoxytryptamine Drugs 0.000 description 1
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 description 1
- LUCHPKXVUGJYGU-XLPZGREQSA-N 5-methyl-2'-deoxycytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 LUCHPKXVUGJYGU-XLPZGREQSA-N 0.000 description 1
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- RAJWOBJTTGJROA-WZNAKSSCSA-N 5alpha-androstane-3,17-dione Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 RAJWOBJTTGJROA-WZNAKSSCSA-N 0.000 description 1
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- UEHOMUNTZPIBIL-UUOKFMHZSA-N 6-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7h-purin-8-one Chemical compound O=C1NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UEHOMUNTZPIBIL-UUOKFMHZSA-N 0.000 description 1
- KHZAOWUHQARJQE-UHFFFAOYSA-N 6-n-[(4-aminophenyl)methyl]-9-methyl-2-n-[[3-(trifluoromethyl)phenyl]methyl]purine-2,6-diamine Chemical compound N1=C(NCC=2C=C(C=CC=2)C(F)(F)F)N=C2N(C)C=NC2=C1NCC1=CC=C(N)C=C1 KHZAOWUHQARJQE-UHFFFAOYSA-N 0.000 description 1
- MAFJMPFLJJCSTB-FQBQTYDJSA-N 7,12-dioxolithocholic acid Chemical compound C1C[C@@H](O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C MAFJMPFLJJCSTB-FQBQTYDJSA-N 0.000 description 1
- DXOCDBGWDZAYRQ-AURDAFMXSA-N 7-oxolithocholic acid Chemical compound C1C[C@@H](O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)CC[C@@H]3[C@]21C DXOCDBGWDZAYRQ-AURDAFMXSA-N 0.000 description 1
- RXMHNAKZMGJANZ-DTTSCKGMSA-N 7alpha,26-dihydroxycholesterol Chemical compound C([C@H]1O)=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(CO)C)[C@@]1(C)CC2 RXMHNAKZMGJANZ-DTTSCKGMSA-N 0.000 description 1
- UQXNEWQGGVUVQA-UHFFFAOYSA-N 8-aminooctanoic acid Chemical compound NCCCCCCCC(O)=O UQXNEWQGGVUVQA-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- OMNVYXHOSHNURL-WPRPVWTQSA-N Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMNVYXHOSHNURL-WPRPVWTQSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108010085443 Anserine Proteins 0.000 description 1
- KDZOASGQNOPSCU-WDSKDSINSA-N Argininosuccinic acid Chemical compound OC(=O)[C@@H](N)CCC\N=C(/N)N[C@H](C(O)=O)CC(O)=O KDZOASGQNOPSCU-WDSKDSINSA-N 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N Cadaverine Natural products NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 235000021513 Cinchona Nutrition 0.000 description 1
- 241000157855 Cinchona Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- VQUZNVATTCZTQO-NUNKFHFFSA-N D-xyluronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)C(O)=O VQUZNVATTCZTQO-NUNKFHFFSA-N 0.000 description 1
- CMUNUTVVOOHQPW-UHFFFAOYSA-O DL-Stachydrine Chemical compound C[N+]1(C)CCCC1C(O)=O CMUNUTVVOOHQPW-UHFFFAOYSA-O 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 description 1
- SXGAGTVDWKQYCX-BQBZGAKWSA-N Glu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O SXGAGTVDWKQYCX-BQBZGAKWSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- JBCLFWXMTIKCCB-VIFPVBQESA-N Gly-Phe Chemical compound NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-VIFPVBQESA-N 0.000 description 1
- AJHCSUXXECOXOY-NSHDSACASA-N Gly-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-NSHDSACASA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZDPYMJNWJWJTAF-HHELISEZSA-N Glycodehydrocholic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C ZDPYMJNWJWJTAF-HHELISEZSA-N 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- HAEJPQIATWHALX-KQYNXXCUSA-J ITP(4-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 HAEJPQIATWHALX-KQYNXXCUSA-J 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- OYIFNHCXNCRBQI-BYPYZUCNSA-N L-2-aminoadipic acid Chemical compound OC(=O)[C@@H](N)CCCC(O)=O OYIFNHCXNCRBQI-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 1
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- NHTGHBARYWONDQ-JTQLQIEISA-N L-α-methyl-Tyrosine Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-JTQLQIEISA-N 0.000 description 1
- MDSUKZSLOATHMH-IUCAKERBSA-N Leu-Val Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C([O-])=O MDSUKZSLOATHMH-IUCAKERBSA-N 0.000 description 1
- RSPURTUNRHNVGF-IOSLPCCCSA-N N(2),N(2)-dimethylguanosine Chemical compound C1=NC=2C(=O)NC(N(C)C)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RSPURTUNRHNVGF-IOSLPCCCSA-N 0.000 description 1
- JFLIEFSWGNOPJJ-JTQLQIEISA-N N(2)-phenylacetyl-L-glutamine Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CC1=CC=CC=C1 JFLIEFSWGNOPJJ-JTQLQIEISA-N 0.000 description 1
- WVGPGNPCZPYCLK-WOUKDFQISA-N N(6),N(6)-dimethyladenosine Chemical compound C1=NC=2C(N(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WVGPGNPCZPYCLK-WOUKDFQISA-N 0.000 description 1
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- FHQDWPCFSJMNCT-UHFFFAOYSA-N N(tele)-methylhistamine Chemical compound CN1C=NC(CCN)=C1 FHQDWPCFSJMNCT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- WVGPGNPCZPYCLK-UHFFFAOYSA-N N-Dimethyladenosine Natural products C1=NC=2C(N(C)C)=NC=NC=2N1C1OC(CO)C(O)C1O WVGPGNPCZPYCLK-UHFFFAOYSA-N 0.000 description 1
- MDSUKZSLOATHMH-UHFFFAOYSA-N N-L-leucyl-L-valine Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(O)=O MDSUKZSLOATHMH-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- SWGXDLRCJNEEGZ-UHFFFAOYSA-N N-cyclohexylformamide Chemical compound O=CNC1CCCCC1 SWGXDLRCJNEEGZ-UHFFFAOYSA-N 0.000 description 1
- BYHJHXPTQMMKCA-QMMMGPOBSA-N N-formyl-L-kynurenine Chemical compound [O-]C(=O)[C@@H]([NH3+])CC(=O)C1=CC=CC=C1NC=O BYHJHXPTQMMKCA-QMMMGPOBSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 1
- AXDLCFOOGCNDST-UHFFFAOYSA-N N-methyl-DL-tyrosine Natural products CNC(C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-UHFFFAOYSA-N 0.000 description 1
- ZYVXHFWBYUDDBM-UHFFFAOYSA-N N-methylnicotinamide Chemical compound CNC(=O)C1=CC=CN=C1 ZYVXHFWBYUDDBM-UHFFFAOYSA-N 0.000 description 1
- ZBSGKPYXQINNGF-UHFFFAOYSA-N N-nicotinoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CN=C1 ZBSGKPYXQINNGF-UHFFFAOYSA-N 0.000 description 1
- DYSDOYRQWBDGQQ-XLPZGREQSA-N N6-Methyl-2'-deoxyadenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 DYSDOYRQWBDGQQ-XLPZGREQSA-N 0.000 description 1
- DYSDOYRQWBDGQQ-UHFFFAOYSA-N N6-Methyldeoxyadenosine Natural products C1=NC=2C(NC)=NC=NC=2N1C1CC(O)C(CO)O1 DYSDOYRQWBDGQQ-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 1
- VQAYFKKCNSOZKM-UHFFFAOYSA-N NSC 29409 Natural products C1=NC=2C(NC)=NC=NC=2N1C1OC(CO)C(O)C1O VQAYFKKCNSOZKM-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 1
- FNPHNLNTJNMAEE-HSZRJFAPSA-N O-octadecanoyl-L-carnitine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C FNPHNLNTJNMAEE-HSZRJFAPSA-N 0.000 description 1
- XOMRRQXKHMYMOC-OAQYLSRUSA-N O-palmitoyl-L-carnitine Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C XOMRRQXKHMYMOC-OAQYLSRUSA-N 0.000 description 1
- QHGUCRYDKWKLMG-MRVPVSSYSA-N Octopamine Natural products NC[C@@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-MRVPVSSYSA-N 0.000 description 1
- 238000010220 Pearson correlation analysis Methods 0.000 description 1
- BXNGIHFNNNSEOS-UWVGGRQHSA-N Phe-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 BXNGIHFNNNSEOS-UWVGGRQHSA-N 0.000 description 1
- JMCOUWKXLXDERB-WMZOPIPTSA-N Phe-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 JMCOUWKXLXDERB-WMZOPIPTSA-N 0.000 description 1
- 241000210053 Potentilla elegans Species 0.000 description 1
- AURFZBICLPNKBZ-UHFFFAOYSA-N Pregnanolone Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 AURFZBICLPNKBZ-UHFFFAOYSA-N 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- JYVXNLLUYHCIIH-ZCFIWIBFSA-N R-mevalonolactone, (-)- Chemical compound C[C@@]1(O)CCOC(=O)C1 JYVXNLLUYHCIIH-ZCFIWIBFSA-N 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
- 229930003761 Vitamin B9 Natural products 0.000 description 1
- CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 description 1
- AJHUPAMRNYNVHR-KQYNXXCUSA-N [[9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]amino]urea Chemical compound N(C(=O)N)NC=1C=2N=CN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C=2N=CN=1 AJHUPAMRNYNVHR-KQYNXXCUSA-N 0.000 description 1
- 229960001009 acetylcarnitine Drugs 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- KXGVEGMKQFWNSR-WFTUMUMQSA-N allodeoxycholic acid Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-WFTUMUMQSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
- GUUHFMWKWLOQMM-NTCAYCPXSA-N alpha-hexylcinnamaldehyde Chemical compound CCCCCC\C(C=O)=C/C1=CC=CC=C1 GUUHFMWKWLOQMM-NTCAYCPXSA-N 0.000 description 1
- 229940072717 alpha-hexylcinnamaldehyde Drugs 0.000 description 1
- GUUHFMWKWLOQMM-UHFFFAOYSA-N alpha-n-hexylcinnamic aldehyde Natural products CCCCCCC(C=O)=CC1=CC=CC=C1 GUUHFMWKWLOQMM-UHFFFAOYSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-UHFFFAOYSA-N alpha-phenylglycine Chemical compound OC(=O)C(N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-UHFFFAOYSA-N 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 229940061641 androsterone Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 229940119740 deoxycorticosterone Drugs 0.000 description 1
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005315 distribution function Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002297 emergency surgery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- SRLROPAFMUDDRC-INIZCTEOSA-N ethyl N-benzoyl-L-tyrosinate Chemical compound C([C@@H](C(=O)OCC)NC(=O)C=1C=CC=CC=1)C1=CC=C(O)C=C1 SRLROPAFMUDDRC-INIZCTEOSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- XHHOHZPNYFQJKL-QWRGUYRKSA-N gamma-Glu-Phe Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XHHOHZPNYFQJKL-QWRGUYRKSA-N 0.000 description 1
- 108010030535 gamma-glutamylphenylalanine Proteins 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 108010084389 glycyltryptophan Proteins 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HSEMFIZWXHQJAE-UHFFFAOYSA-N hexadecanamide Chemical compound CCCCCCCCCCCCCCCC(N)=O HSEMFIZWXHQJAE-UHFFFAOYSA-N 0.000 description 1
- 229940081141 hexadecanamide Drugs 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- 229940040102 levulinic acid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- HLZXTFWTDIBXDF-UHFFFAOYSA-N mcm5sU Natural products COC(=O)Cc1cn(C2OC(CO)C(O)C2O)c(=S)[nH]c1=O HLZXTFWTDIBXDF-UHFFFAOYSA-N 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229940057061 mevalonolactone Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- FWGROIXQKFUTAY-UHFFFAOYSA-N n-(1-aminobutyl)acetamide Chemical compound CCCC(N)NC(C)=O FWGROIXQKFUTAY-UHFFFAOYSA-N 0.000 description 1
- CYDFBLGNJUNSCC-QCNRFFRDSA-N n-[1-[(2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-2-oxopyrimidin-4-yl]acetamide Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(NC(C)=O)C=C1 CYDFBLGNJUNSCC-QCNRFFRDSA-N 0.000 description 1
- 229960001576 octopamine Drugs 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 description 1
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000010239 partial least squares discriminant analysis Methods 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- HVAMZGADVCBITI-UHFFFAOYSA-N pent-4-enoic acid Chemical compound OC(=O)CCC=C HVAMZGADVCBITI-UHFFFAOYSA-N 0.000 description 1
- GKZIWHRNKRBEOH-UHFFFAOYSA-N phenylalanylphenylalanine Chemical compound C=1C=CC=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 GKZIWHRNKRBEOH-UHFFFAOYSA-N 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 108010083476 phenylalanyltryptophan Proteins 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- RHFUOMFWUGWKKO-UHFFFAOYSA-N s2C Natural products S=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 RHFUOMFWUGWKKO-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 1
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- JKLRIMRKZBSSED-UHFFFAOYSA-N taurocyamine Chemical compound NC(=[NH2+])NCCS([O-])(=O)=O JKLRIMRKZBSSED-UHFFFAOYSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 235000020955 thiamine monophosphate Nutrition 0.000 description 1
- 239000011621 thiamine monophosphate Substances 0.000 description 1
- 229960002363 thiamine pyrophosphate Drugs 0.000 description 1
- 235000008170 thiamine pyrophosphate Nutrition 0.000 description 1
- 239000011678 thiamine pyrophosphate Substances 0.000 description 1
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 1
- GUGWNSHJDUEHNJ-UHFFFAOYSA-N thiamine(1+) monophosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N GUGWNSHJDUEHNJ-UHFFFAOYSA-N 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- GTZCVFVGUGFEME-HNQUOIGGSA-N trans-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C/C(O)=O GTZCVFVGUGFEME-HNQUOIGGSA-N 0.000 description 1
- GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- YIZYCHKPHCPKHZ-UHFFFAOYSA-N uridine-5-acetic acid methyl ester Natural products COC(=O)Cc1cn(C2OC(CO)C(O)C2O)c(=O)[nH]c1=O YIZYCHKPHCPKHZ-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UTLSPDKDSA-N ursocholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-UTLSPDKDSA-N 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 235000019159 vitamin B9 Nutrition 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- FBZONXHGGPHHIY-UHFFFAOYSA-N xanthurenic acid Chemical compound C1=CC=C(O)C2=NC(C(=O)O)=CC(O)=C21 FBZONXHGGPHHIY-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明涉及生物检测技术领域,具体提供了一种预测房颤发生风险的检测试剂盒及其应用,本发明提供的生物标志物或者生物标志物组合物,预测房颤发生风险有良好的敏感性和特异性,具备临床应用前景。
Description
技术领域
本发明涉及生物检测技术领域,具体涉及一种预测房颤发生风险的检测试剂盒及其应用。
背景技术
心房颤动(Atrial Fibrillation,AF),简称房颤,是临床上最常见的心律失常,发病率正随着人口老龄化的发展而显著上升,流行病学资料显示,目前全球房颤患者已高达4000万人,且正以每年200万人的速度逐年递增。
房颤与诸多心血管不良事件紧密相关,可导致患者的心室率(律)紊乱,严重时甚至出现室颤或者心脏骤停;促使血栓形成,并发脑卒中;长期房颤可引发和加重心力衰竭等,严重危害患者健康,加重医疗费用负担。而目前国内外有关房颤预测的研究成果,预测效能较低,并且很少应用于临床实践,使得房颤难以被早期预警、早期干预,因此本领域迫切需要开发能够有效预测房颤发病风险的生物标志物。
发明内容
因此,本发明的目的在于提供用于预测房颤风险的生物标志物,具体提供了一种预测房颤发生风险的检测试剂盒及其应用。
本发明提供了一种生物标志物在制备预测心房颤动发生风险的产品中的用途,所述生物标志物选自鸟氨酸、乙酰谷酰胺、尿嘧啶、2-甲氧基苯甲酸、异胞嘧啶、N-乙酰-L-酪氨酸、2'-O-甲基胞苷、肌醇、精氨酸或者甲硫氨酸。
本发明还提供了一种用于预测心房颤动发生风险的生物标志物组合物,所述生物标志物组合物包括精氨酸、鸟氨酸、乙酰谷氨酸和甲硫氨酸。
进一步地,所述生物标志物组合物包含鸟氨酸、乙酰谷酰胺、尿嘧啶、2-甲氧基苯甲酸、异胞嘧啶、N-乙酰-L-酪氨酸、2'-O-甲基胞苷、肌醇、尿刊酸、L-亮氨酸、1,5-酐-D-山梨糖醇和精氨酸。
进一步地,所述生物标志物组合物还包含甲硫氨酸。
本发明还提供了任一所述的生物标志物组合物在制备用于预测心房颤动风险的产品中的用途。
进一步地,所述产品为试剂盒。
进一步地,所述试剂盒包括生物标志物的标准品;优选的,优选的,所述试剂盒还包括溶剂1、溶剂2和溶剂3,其中溶剂1为体积百分数15-25%乙腈和75-85%甲醇的混合液,溶剂2为含8-12mM乙酸铵和体积百分数为0.2-0.4%氨水的水溶液,溶剂3为体积百分比为85-95%乙腈和5-15%水的混合液。氨水为浓氨水,例如每100mL含10mM乙酸铵的水溶液中加入0.3mL的浓氨水。
进一步地,所述预测是检测待测受试者血清或血浆中的生物标志物或者生物标志物组合物的水平值,若当受试者血清或血浆中上述任一种生物标准物的水平值或者上述任一所述的生物标志物组合物中的每一种生物标志物的水平值低于参考值下限或高于参考值上限时,则所述受试者具有发生心房颤动的风险。
其中,本发明中的参考值下限和参考值上限分别为对照人群水平的第5百分位数和第95百分位数。
具体地,对于鸟氨酸、乙酰谷酰胺、尿嘧啶、2-甲氧基苯甲酸、N-乙酰-L-酪氨酸、肌醇、尿刊酸、L-亮氨酸、1,5-酐-D-山梨糖醇、精氨酸或者甲硫氨酸来说,低于参考值下限时,则所述受试者具有发生心房颤动的风险,对于异胞嘧啶、2'-O-甲基胞苷来说,高于参考值上限时,则所述受试者具有发生心房颤动的风险。
进一步地,通过质谱联用液相色谱法测定生物标志物的水平。
进一步地,所述心房颤动发生风险是指心脏外科手术术后发生心房颤动的风险。
本发明中,心脏外科手术是指主要通过开胸或者胸腔镜完成的手术,包括冠状动脉旁路移植手术、瓣膜修复手术或者瓣膜置换手术,还包括先天性心脏病开胸修补手术等。
本发明还提供了一种预测心房颤动发生风险的试剂盒,包括任一所述的生物标志物组合物。
本发明还提供了所述的生物标志物或者所述的生物标志物组合物在制备用于筛选预防或治疗心房颤动的药物中的用途。
本发明技术方案,具有如下优点:
1. 本发明研究发现,鸟氨酸、乙酰谷酰胺、尿嘧啶、2-甲氧基苯甲酸、异胞嘧啶、N-乙酰-L-酪氨酸、2'-O-甲基胞苷、肌醇、精氨酸或者甲硫氨酸可作为生物标志物,这些生物标志物预测房颤发生风险有良好的敏感性和特异性,具备临床应用前景。
2. 本发明所述生物标志物,可以包含精氨酸、鸟氨酸、乙酰谷氨酸和甲硫氨酸的组合物。尤其是包含鸟氨酸、乙酰谷酰胺、尿嘧啶、2-甲氧基苯甲酸、异胞嘧啶、N-乙酰-L-酪氨酸、2'-O-甲基胞苷、肌醇、尿刊酸、L-亮氨酸、1,5-酐-D-山梨糖醇和精氨酸的组合物,具有较高的敏感性和特异性。
更加突出的是,上述组合物中还包含甲硫氨酸时,具有更高的敏感性和特异性。
附图说明
为了更清楚地说明本发明具体实施方式或现有技术中的技术方案,下面将对具体实施方式或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图是本发明的一些实施方式,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1是对同一质控样本质谱检测分析的总离子流图(TIC)重叠图;
图2是QC样本相关性分析;
图3是各组样本中CV分布图;
图4是鸟氨酸和乙酰谷酰胺用于预测心房颤动的 ROC 曲线;
图5是尿嘧啶和2-甲氧基苯甲酸用于预测心房颤动的 ROC 曲线;
图6是异胞嘧啶和N-乙酰-L-酪氨酸用于预测心房颤动的 ROC 曲线;
图7是2'-O-甲基胞苷和肌醇用于预测心房颤动的 ROC 曲线;
图8是精氨酸和甲硫氨酸用于预测心房颤动的 ROC 曲线;
图9是组合1(即精氨酸、鸟氨酸、乙酰谷氨酸和甲硫氨酸的组合)的水平用于预测心房颤动的 ROC 曲线;
图10是组合2(即鸟氨酸、乙酰谷酰胺、尿嘧啶、2-甲氧基苯甲酸、异胞嘧啶、N-乙酰-L-酪氨酸、2'-O-甲基胞苷、肌醇、尿刊酸、L-亮氨酸、1,5-酐-D-山梨糖醇和精氨酸的组合)的水平用于预测心房颤动的 ROC 曲线;
图11是组合3(即鸟氨酸、乙酰谷酰胺、尿嘧啶、2-甲氧基苯甲酸、异胞嘧啶、N-乙酰-L-酪氨酸、2'-O-甲基胞苷、肌醇、尿刊酸、L-亮氨酸、1,5-酐-D-山梨糖醇、精氨酸和甲硫氨酸的组合)的水平用于预测心房颤动的 ROC 曲线。
具体实施方式
提供下述实施例是为了更好地进一步理解本发明,并不局限于所述最佳实施方式,不对本发明的内容和保护范围构成限制,任何人在本发明的启示下或是将本发明与其他现有技术的特征进行组合而得出的任何与本发明相同或相近似的产品,均落在本发明的保护范围之内。
实施例中未注明具体实验步骤或条件者,按照本领域内的文献所描述的常规实验步骤的操作或条件即可进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规试剂产品。
实施例1
1、临床样品
在首都医科大学附属北京安贞医院符合心脏外科手术适应症并进行手术的患者纳入本研究,所有研究对象术前没有心房颤动,实验组人群是心脏外科术后(冠状动脉旁路移植手术)经心电图确诊的房颤患者,共101例。参加本研究的所有对照人群在心脏外科术后(冠状动脉旁路移植手术)同一时期中的医学检查中没有出现心电图确诊的房颤,共101例。
房颤诊断标准:完整的12导联心电图记录到房颤特征性心电图表现,或者单导联记录超过30秒,特征心电图表现为:(1)“绝对”不规则R-R间期(无完全房室传导阻滞的基础上);(2)体表心电图上无明显P波;(3)心房周期长度(可见时)常小于200毫秒。
参考文献:《心房颤动外科治疗中国专家共识2020版》
注意事项:排除标准是既往房颤史,合并瓣膜病、肿瘤或者甲状腺疾病,二次或急诊手术,服用过或正在服用抗心律失常药物,拒绝参与实验的患者。
2、质谱联用液相色谱技术检测化合物水平
主要仪器:LC-MS/MS,型号QTRAP 6500+,品牌SCIEX。
血浆样本采集:采集房颤患者和健康对照人群空腹状态下静脉血1ml,3000 rpm×10min 离心后留取上清于-80℃冻存。
血浆样本的前处理:(1)样本解冻后,涡旋10 s混匀;(2)取样本50 μL(取完样的样本尽快放回-80 ℃冰箱保存)加入到对应的已编号的1.5 mL离心管中,加入250 μL溶剂1(体积百分数20 %乙腈和80%甲醇的混合液);(3)涡旋3 min后离心,12000 r/min,4 ℃条件下离心10 min;(4)离心完后吸取上清液250 μL到另一个编好号的1.5 mL离心管中,-20℃冰箱中静置30 min;(5)12000 r/min,4 ℃条件下再离心10 min;(6)取180 μL上清液过蛋白沉淀板后用于上机通过HPLC-MS进行代谢谱分析,上机液置于-20℃保存。从每个血浆样本中取出等体积(10μL)样品并混合均匀,将其作为“质量控制”(QC)样本,该样本用于估计一个能够代表在分析过程中所遇到的所有分析物的“平均”谱(profile)。每隔10个检测分析样本插入一个质控样本,以进一步监测系统稳定性。
(1)检测方法:液相色谱采用的是梯度洗脱的方法,色谱柱选择 ACQUITY UPLCBEH Amide 柱(1.7 µm, 100 mm×2.1 mm i.d.),流动相:A相,溶剂2:超纯水(10mM乙酸铵,体积百分数为0.3%氨水);B相,溶剂3:90%乙腈/10%水(V/V),流速0.40 mL/min;柱温40°C;进样量2 μL ;流动相梯度:0-1.2 min A/B为5:95(V/V),8 min A/B为30:70(V/V),9.0-11min A/B为50:50(V/V),11.1-15 min A/B为5:95(V/V)。质谱条件:电喷雾离子源(Electrospray Ionization,ESI)温度550℃,正离子模式下质谱电压 5500 V,负离子模式下质谱电压-4500 V,气帘气(Curtain Gas,CUR)35 psi。在Q-Trap 6500+ 中,每个离子对是根据优化的去簇电压(Declustering Potential,DP)和碰撞能(Collision Energy,CE)进行扫描检测。
标准品溶液的制备:配制0.01 ng/mL、0.02 ng/mL、0.05 ng/mL、0.1 ng/mL、0.2ng/mL、0.5 ng/mL、1 ng/mL、2 ng/mL、5 ng/mL、10 ng/mL、20 ng/mL、50 ng/mL、100 ng/mL、200 ng/mL、500 ng/mL、1000 ng/mL、2000 ng/mL、5000 ng/mL、10000 ng/mL、20000 ng/mL不同浓度的标准品溶液。标准品分别是2-羟基十六烷酸、十八烷二酸、没食子酸、十六烷-1,16-二酸、吲哚-3-乙酸甲酯、水杨酸、高香草酸、3-羟基异戊酸、苯丙酮酸、2-糠酸、2,5-二羟基苯甲酸、原儿茶酸、苯甲酸、尿囊素、辛二酸、黄尿酸/黄嘌呤酸、肌苷、DL-3-苯乳酸、喹啉酸、对羟基苯甲酸、马尿酸、羟基异己酸、alpha-亚麻酸、延胡索酸/富马酸、羟基癸酸、石胆酸、5-甲基尿苷、肌醇、甲基丙二酸/异琥珀酸、猪脱氧胆酸、苯乙醛酸、4-羟苯基丙酮酸、Alpha-酮戊二酸、乙酰丙酸、alpha-羟基异丁酸、二羟基苯基乙酸、3-羟基邻氨基苯甲酸、肠二醇、3,4-二甲氧基苯乙酸、1,3-二甲基尿酸、DL-泛醇、4-羟基苯甲醛、苯丙氨酰苯丙氨酸、2-羟基-2-甲基丁酸、尿黑酸、甘氨胆酸、1,7-二甲基尿酸、5,6-二羟基吲哚-2-羧酸、6-羟基褪黑素、甘氨石胆酸、3-羟基-5-胆甾烯酸酯、生物蝶呤、己酰甘氨酸、苯乙酰谷氨酰胺、3-羟基-3-甲基谷氨酸、反式-乌头酸、乙基丙二酸、2-(甲酰氨基)苯甲酸、环腺苷酸、2,4-二羟基苯甲酸、3-甲基-2-氧代戊酸、咖啡酸、三碘甲状腺原氨酸、3,4,5-三甲氧基苯甲酸、6-磷酸葡萄糖酸、泛酸、苯氧乙酸、蓖麻油酸、甘氨酰-L-缬氨酸、N-L-gamma-谷氨酰-L-亮氨酸、对甲酚硫酸盐铵盐、2,6 -二异丙基Β- D -吡喃葡萄糖酸、3-甲基水杨酸、硫酸脱氢表雄酮、衣康酸、异亮氨酰-异亮氨酸、隐绿原酸、3-(3-羟基苯基)-3-羟基丙酸、omega-鼠胆酸、甘氨石胆酸-3-硫酸盐、甘氨猪去氧胆酸、3-氧代胆酸、鹅去氧胆酸24-酰基-beta-D-葡糖苷酸、7-酮基脱氧胆酸、去甲胆酸、熊胆酸、5-羟甲基-2-呋喃甲酸、吲哚丙酮酸、12,13-DiHOME、尿嘧啶-5-羧酸、3-甲氧基苯甲酸、3-羟基丁酸、朱砂精酸、鼠尾草酸、吲哚-3-乙酰胺、牛磺猪胆酸、牛磺-beta-鼠胆酸、牛磺熊去氧胆酸、甘氨脱氧胆酸、甘氨鹅脱氧胆酸、鹅脱氧胆酸、牛磺胆酸、甘氨猪胆酸、牛磺石胆酸、3beta-胆酸、脱氧胸苷酸、3-羟基-2-吡啶甲酸、2-羟基-3-甲基丁酸、N-肉桂基甘氨酸、3,4-二羟基苯丙酸、戊烯二酸、12-羟基十二酸、beta-鼠胆酸、猪胆酸、7-酮基石胆酸、12-酮基石胆酸、7,12-二酮石胆酸、甘氨脱氢胆酸、牛磺脱氢胆酸、23-脱甲脱氧胆酸、别脱氧胆酸、异石胆酸、别异石胆酸、牛磺鹅脱氧胆酸、胆酸、牛磺脱氧胆酸、脱氢石胆酸、3-氧代-12alpha羟基-24胆酸、3beta-脱氧胆酸、3,5-二碘-L-甲状腺原氨酸、邻羟基苯乙酸、4-甲氧基苯乙酸、4-羟基-3-甲基苯甲酸、(E)-3-吲哚丙烯酸、3-(4-羟基苯基)乳酸、2-氨基-3-甲氧基苯甲酸、苯丁酸、甜蜜素、2-氨基-5-羟基苯甲酸、戊二酸、2-甲基丁酰肉碱、2-甲氧基苯甲酸、酪胺、色胺、3-甲氧酪胺、亚精胺、腺苷、2-氮己环酮、吲哚-2-羧酸、DL-3-甲氧基肾上腺素盐酸盐、1-十八碳烯基-sn-甘油-3-磷酸胆碱、嘌呤、1,5-戊二胺、亮氨酸、苯丙氨酸、犬尿氨酸、酪氨酸、次黄嘌呤、组氨酸、异亮氨酸、鸟嘌呤、色氨酸、1-十六烷酰基-sn-甘油-3-磷酸胆碱、溶血磷脂酰乙醇胺、5-甲氧基色胺、尿刊酸、顺式-10-十七碳烯酸、N6,N6,2’-O-三甲基腺苷、5-十二碳烯酸、吲哚-3-乙醛酸、维生素B9/叶酸、二氢睾酮、雄酮、5beta-雄甾酮、脱氢表雄酮、对乙酰氨基酚、3-氨基水杨酸、胸苷、腐胺、5,2’-O-甲基胞苷、N4-乙酰基-2’-O-甲基胞苷、5-甲酰基-2'-O-甲基胞苷、1-甲基伪尿苷、N4,2'-O-甲基胞苷、肾上腺素、6-甲基尿苷、2-硫-2'-O-甲基尿苷、雌酮、N-甲基烟酰胺、苯乙胺、蛋氨酸(甲硫氨酸)、多巴(左旋多巴)、甲状腺素、吡啶甲酸、邻苯二甲酸、N-乙酰-L-酪氨酸、氢化可的松、17alpha-炔雌醇、去氧皮质酮、17a-羟孕酮、咖啡因、原儿茶醛、棕榈酰乙醇酰胺(PEA)、3-碘化酪氨酸、左旋肌肽、多巴胺、L-O-磷酸丝氨酸、5-羟基吲哚-3-乙酸、p-氨基马尿酸、吡咯-2-羧酸、DL-2-氨基辛酸、环磷酸鸟苷、5-甲氧基吲哚-3-乙酸、N-甲基色胺、皮质酮、3-吲哚乳酸、乙酰谷酰胺、4-乙酰氨基丁酸、吲哚-3-甲醛、吲哚-3-丁酸、S-(5-腺苷)-L-高半胱氨酸、二氢尿嘧啶、二氢胸腺嘧啶、苯乙酰甘氨酸、副黄嘌呤、黄嘌呤核苷、N-乙酰-5-羟色胺、1-甲基黄嘌呤、7-甲基黄嘌呤、N-甲酰基犬尿氨酸、脱氧可的松、骨化二醇、7-羟基-4-胆甾烯-3-酮、20alpha-羟基胆固醇、醛固酮、7-酮胆固醇、烟酰甘氨酸、11-酮本胆烷醇酮、N-甘氨酰-L-亮氨酸、孕烯醇酮、睾酮、17alpha-雌二醇、17beta-雌二醇、雄烯二酮、可的松、黄体酮NA孕酮、二氢黄体酮、5beta-孕烷-3alpha,20alpha-二醇、L-棕榈酰肉碱、3-甲氧基肾上腺素、7alpha,25-二羟基胆固醇、1,3,7-三甲基尿酸、(3beta,24S)-胆甾-5-烯-3,24-二醇、11-去氢皮质甾酮、3-羟基马尿酸、17alpha-羟基妊娠烯醇酮、7a,27-Dihydroxycholesterol、二甲基鸟苷、7-甲基鸟嘌呤、N8-乙酰基亚精胺、5’-脱氧-5’-甲基硫代腺苷、异戊酰肉碱、异丁酰-L-肉碱、月桂酰肉碱/十二烷酰基左旋肉碱、硬脂酰肉毒碱、癸酰氯化肉碱、辛酰氯化肉碱、褪黑素、吲哚-3-羧酸、熊果酸、对-氨基苯甲酸、光色素、1,25-二羟基维生素D2、L-正亮氨酸、山楂酸、蜕皮激素、胡椒碱、对甲氧基苯甲酸、alpha-己基肉桂醛、2-苯基乙酰胺、丙二酸二乙酯、异戊胺、酪氨酸甲酯、环己胺、正丁胺、己胺、二苯胺、对甲氧基苯甲醛、二氢茉莉酮酸甲酯、N-苯甲酰-L-酪氨酸乙酯、1-单棕榈酸、4-戊烯酸、3-硝基酪氨酸、gamma-谷氨酰苯丙氨酸、1-十四酰-2-羟基卵磷脂、缓激肽、5-碘吡啶胞苷、5'-脱氧腺苷、十六碳酰胺、油酸酰胺、7-甲基鸟苷、4-硫尿苷、3-甲基尿苷、5,2'-O-甲基尿苷、N6,N6-二甲基腺苷、O6-甲基鸟苷、5-甲氧羰基甲基尿苷、2-硫胞苷、N6-苏氨甲酰氨基腺苷、N2,N2,7-三甲基鸟苷、5-甲氧羰基甲基-2-硫尿苷、5-甲氧基尿苷、8-羟基腺苷、N6,2’-O-二甲基腺苷、5-甲酰基胞苷、亚油酰胺、组氨酸-色氨酸、N-环己基甲酰胺、对甲基苯甲酸、苯丙氨酰色氨酸、16alpha羟基雌酮、2-甲氧基雌酮、4-甲氧基雌酮、2-羟基雌酮、beta-吲哚-3-乙酸、L-焦谷氨酸、肉桂酸、4-羟基马尿酸、5-甲基-2'-脱氧胞苷、N6-甲基-2'-脱氧腺苷、甲瓦龙酸内酯、别孕烯醇酮、奥昔嘌醇、利他宁酸、苯胺、3-(2-羟苯基)丙酸、2-喹啉羧酸、8-氨基辛酸、L-亮氨酸-L-丙氨酸、邻氨基苯甲酸、5-羟基色胺/血清素、L-丙氨酰-L-苯丙氨酸、甘氨酰苯基丙氨酸、甘氨酰-色氨酸、吡咯、5alpha-雄甾烷二酮、11-beta-羟基雄酮、2’-O-甲基尿苷、鸟苷、3-吲哚乙醇、醋酸甲羟孕酮、脱硫生物素、L-亮氨酸酰基-L-缬氨酸、谷氨酰基-蛋氨酸、苯丙氨酰蛋氨酸、L-苯丙氨酰-L-亮氨酸、烟酰胺、L-苯丙氨酰基-L-天冬酰胺、冬胺基乙酸-苯丙胺基乙酸、苯丙氨酰缬氨酸、章鱼胺、3-甲基羟基吲哚、5-羟基赖氨酸、左甲状腺素、犬尿喹啉酸/犬尿酸、戊酸、L-甘氨酸-L-异亮氨酸、2’-O-甲基鸟苷、3-氯-L-酪氨酸、2-(3,4-二甲氧基苯基)乙胺、6-二甲基氨基嘌呤、2-苯甘氨酸、苯甲酰胺、5-羟基色氨酸、维A酸、硫胺素焦磷酸、环二腺苷酸、维生素B6(吡哆醛)、腺嘌呤、胞嘧啶、金鸡纳酸、D-木糖醛酸、莽草酸、2-氨基乙烷磺酸/牛磺酸、谷氨酸盐(谷氨酸)、苏氨酸、丝氨酸、L-天冬酰胺、D-木酮糖5-磷酸、腺苷酸、磷酸二羟丙酮、尿苷5-单磷酸、L-瓜氨酸、脱氧胞苷酸、海藻糖、4-磷酸赤藓糖、鸟苷酸、NADP、葡萄糖-6-磷酸、磷酸乙醇胺、三磷酸腺苷、二磷酸腺苷、N-异戊酰氨基乙酸、gama-谷氨酰-丙氨酸、N-乙酰-L-谷氨酸、尿嘧啶、烟酰胺腺嘌呤二核苷酸、肌苷-1-磷酸、3-磷酸甘油、核黄素磷酸钠、生物素、癸二酸、柠檬酸、5-羟甲基尿嘧啶、山梨酸、古洛糖酸内酯、(3R,4R)-D-赤酮酸内酯、D-葡醛内酯、2-羟基-6-氨基嘌呤、1,5-酐-D-山梨糖醇、DL-水苏碱、胆碱、甜菜碱醛氯化物、甜菜碱、D-甘露糖、胸腺嘧啶、5-羧基胞苷、尿素、肌酸酐、2'-脱氧胞苷、胞嘧啶核苷、5-羟甲基-2'-脱氧胞苷、5-羟甲基胞苷、N,N-二甲基甘氨酸、亚牛磺酸、肌氨酸、丙氨酸、维生素B6(盐酸吡哆胺)、氨基甲酰天冬氨酸、乙酰胆碱、甘氨酸、乙酸胍、肉毒碱、4-氨基丁酸/gamma-氨基丁酸、谷氨酰胺、4-羟基-1-L-脯氨酰-L-脯氨酸、L-天冬氨酸、乙醇胺、磷酸胆碱、胞苷一磷酸(CMP)、胱氨酸、精氨基琥珀酸、组胺、ITP、S-腺苷甲硫氨酸、鸟氨酸、精氨酸、赖氨酸、高精氨酸、丙氨酰-丙氨酸、眯基牛磺酸、缬氨酸、脯氨酸、哌啶酸、N-乙酰神经氨酸、2-氨基异丁酸、氨基异丁酸、氧化三甲胺、4-羟基-L-脯氨酸、N6-乙酰-L-赖氨酸、肌酸、甘氨酰-L-脯氨酸、同型丝氨酸、蛋氨酸亚砜、β-氨基丙酸、a-氨基已二酸、3-N-甲基-L-组氨酸、高瓜氨酸、5-氨基戊酸、鹅肌肽、高胱氨酸、氧化型谷胱甘肽、胱硫醚、三甲胺、尿苷、N1-甲基肌苷、2’-O-甲基肌苷、乙酰肉碱、假尿苷、2-脱氧尿苷、1-甲基腺苷、核黄素-5-磷酸、N-Α-乙酰-L-精氨酸、2’-O-甲基腺苷、N6-甲基腺苷、1-甲基鸟苷、N2-甲基鸟苷、2'-脱氧鸟苷、5-甲基胞苷、2’-O-甲基胞苷、硫胺素单磷酸盐、硫鸟嘌呤、3-甲基腺嘌呤、四氢吡咯、1-甲基组胺、葫芦巴碱、N-乙酰基-D-半乳糖胺、三乙胺、5-甲基胞嘧啶、1-甲基腺嘌呤、L-去氧肾上腺素、异胞嘧啶、L-正缬氨酸、D-甘露糖胺、gama-O-十八烷基-L-alpha-溶血卵磷脂、N-乙酰丁二胺。
测试:取标准品溶液、处理后的待测血样本各2微升上机检测。获取254个代谢物的各个浓度标准品的对应定量信号的质谱峰强度数据;以外标与内标浓度比或外标浓度(Concentration Ratio or Concentration)为横坐标,外标与内标峰面积比或外标峰面积(Area Ratio or Area)为纵坐标,绘制如下共254种代谢物的标准曲线,代谢物包括:氨基异丁酸、1,3,7-三甲基尿酸、1,3-二甲基尿酸、1,5-酐-D-山梨糖醇、1,7-二甲基尿酸、顺式-10-十七碳烯酸、12,13-DiHOME、蓖麻油酸、17alpha-雌二醇、17a-羟孕酮、溶血磷脂酰乙醇胺、1-甲基腺苷、1-甲基鸟苷、1-甲基伪尿苷、1-甲基黄嘌呤、1-十四酰-2-羟基卵磷脂、gama-O-十八烷基-L-alpha-溶血卵磷脂、1-十八碳烯基-sn-甘油-3-磷酸胆碱、2,5-二羟基苯甲酸、邻氨基苯甲酸、2-氨基异丁酸、DL-2-氨基辛酸、羟基癸酸、2-羟基十六烷酸、2-羟基-3-甲基丁酸、吲哚-2-羧酸、2-甲氧基苯甲酸、2-甲基丁酰肉碱、alpha-羟基异丁酸、2’-O-甲基胞苷、2’-O-甲基鸟苷、吡啶甲酸、2-氮己环酮、3-(3-羟基苯基)-3-羟基丙酸、三碘甲状腺原氨酸、3beta-胆酸、3beta-脱氧胆酸、3-羟基-5-胆甾烯酸酯、3-羟基丁酸、3-羟基马尿酸、3-羟基异戊酸、3-羟基-3-甲基谷氨酸、多巴胺、吲哚-3-丁酸、3-甲氧酪胺、3-甲基羟基吲哚、3-甲基水杨酸、3-N-甲基-L-组氨酸、3-氧代胆酸、3-氧代-12alpha羟基-24胆酸、DL-3-苯乳酸、4-乙酰氨基丁酸、4-羟基苯甲醛、对羟基苯甲酸、5’-脱氧-5’-甲基硫代腺苷、5-甲酰基胞苷、5-羟基赖氨酸、5-甲氧羰基甲基-2-硫尿苷、5-甲基尿苷、7,12-二酮石胆酸、7-羟基-4-胆甾烯-3-酮、7-酮基脱氧胆酸、7-甲基黄嘌呤、8-氨基辛酸、乙酰谷酰胺、对乙酰氨基酚、乙酰肉碱、L-丙氨酰-L-苯丙氨酸、尿囊素、a-氨基已二酸、alpha-己基肉桂醛、alpha-亚麻酸、5alpha-雄甾烷二酮、精氨酸、精氨基琥珀酸、苯甲酸、β-氨基丙酸、beta-吲哚-3-乙酸、甜菜碱、生物素、缓激肽、正丁胺、咖啡酸、咖啡因、环磷酸鸟苷、鹅脱氧胆酸、鹅去氧胆酸24-酰基-beta-D-葡糖苷酸、胆酸、磷酸胆碱、朱砂精酸、脱氧可的松、皮质酮、氢化可的松、可的松、肌酸、肌酸酐、甜蜜素、环己胺、胞嘧啶核苷、丙氨酰-丙氨酸、癸酰氯化肉碱、脱氢表雄酮、硫酸脱氢表雄酮、去氧皮质酮、(3R,4R)-D-赤酮酸内酯、丙二酸二乙酯、二氢胸腺嘧啶、N,N-二甲基甘氨酸、肉毒碱、月桂酰肉碱/十二烷酰基左旋肉碱、雌酮、乙基丙二酸、3,4,5-三甲氧基苯甲酸、延胡索酸/富马酸、gama-谷氨酰-丙氨酸、谷氨酰基-蛋氨酸、gamma-谷氨酰苯丙氨酸、谷氨酰胺、戊二酸、3-磷酸甘油、甘氨酸、甘氨鹅脱氧胆酸、甘氨胆酸、甘氨脱氢胆酸、甘氨脱氧胆酸、甘氨猪去氧胆酸、甘氨石胆酸、甘氨酰苯基丙氨酸、甘氨酰-色氨酸、甘氨酰-L-缬氨酸、鸟苷酸、乙酸胍、鸟嘌呤、鸟苷、十六碳酰胺、十六烷-1,16-二酸、己酰甘氨酸、N-L-gamma-谷氨酰-L-亮氨酸、组氨酸-色氨酸、马尿酸、组氨酸、尿黑酸、高香草酸、苯丙氨酰色氨酸、猪脱氧胆酸、亚牛磺酸、次黄嘌呤、吲哚丙酮酸、(E)-3-吲哚丙烯酸、3-吲哚乳酸、肌苷、别异石胆酸、异丁酰-L-肉碱、异胞嘧啶、异石胆酸、异戊酰肉碱、犬尿氨酸、丙氨酸、冬胺基乙酸-苯丙胺基乙酸、L-天冬酰胺、L-天冬氨酸、L-瓜氨酸、胱氨酸、L-亮氨酸酰基-L-缬氨酸、L-亮氨酸-L-丙氨酸、乙酰丙酸、谷氨酸盐(谷氨酸)、高瓜氨酸、高胱氨酸、亚油酰胺、异亮氨酸、羟基异己酸、亮氨酸、蛋氨酸(甲硫氨酸)、L-正亮氨酸、L-棕榈酰肉碱、脯氨酸、L-焦谷氨酸、光色素、缬氨酸、赖氨酸、蛋氨酸亚砜、肌醇、二甲基鸟苷、N2,N2,7-三甲基鸟苷、N2-甲基鸟苷、N6,2’-O-二甲基腺苷、N6-乙酰-L-赖氨酸、N6-苏氨甲酰氨基腺苷、N-Α-乙酰-L-精氨酸、N-乙酰-L-谷氨酸、N-乙酰-L-酪氨酸、N-甲酰基犬尿氨酸、烟酰胺、烟酰甘氨酸、23-脱甲脱氧胆酸、十八烷二酸、辛酰氯化肉碱、油酸酰胺、鸟氨酸、棕榈酰乙醇酰胺(PEA)、泛酸、副黄嘌呤、L-苯丙氨酰-L-亮氨酸、苯丙氨酰蛋氨酸、苯丙氨酰苯丙氨酸、苯丙氨酰缬氨酸、苯乙酰甘氨酸、苯氧乙酸、苯乙酰谷氨酰胺、苯丙氨酸、邻苯二甲酸、胡椒碱、4-羟基-1-L-脯氨酰-L-脯氨酸、2,6 -二异丙基Β- D -吡喃葡萄糖酸、原儿茶酸、假尿苷、吡咯-2-羧酸、金鸡纳酸、2-喹啉羧酸、维A酸、S-(5-腺苷)-L-高半胱氨酸、水杨酸、丝氨酸、5-羟基色胺/血清素、莽草酸、亚精胺、DL-水苏碱、硬脂酰肉毒碱、辛二酸、2-氨基乙烷磺酸/牛磺酸、牛磺-beta-鼠胆酸、牛磺鹅脱氧胆酸、牛磺胆酸、牛磺脱氢胆酸、牛磺脱氧胆酸、睾酮、苏氨酸、甲状腺素、4-羟基-L-脯氨酸、反式-乌头酸、海藻糖、葫芦巴碱、氧化三甲胺、色氨酸、酪氨酸、尿苷5-单磷酸、尿嘧啶、尿素、尿苷、尿刊酸、熊胆酸、黄尿酸/黄嘌呤酸、D-木糖醛酸。
本项目所检测的部分代谢物的标准曲线现行方程及相关系数见下表。
注:Index:物质简称;Equation为线性方程;r为相关系数(Coefficient ofCorrelation);Weighting为权重;LLOQ(ng/mL)和ULOQ(ng/mL)分别是定量下限和定量上限,两者范围内可准确定量。
将检测到的所有样本的积分峰面积代入标准曲线线性方程进行计算,进一步代入计算公式计算后,最终得到实际样本中该物质的含量数据。注意:计算公式已进行单位换算,直接将对应数值代入即可得到样本含量。
样本中各物质的含量(ng/mL)= c×V1/1000/V2
公式中各字母含义:
c:样本中积分峰面积代入标准曲线得到的浓度值(ng/mL);
V1:提取液总体积(μL);
V2:移取的样本量(mL)。
3、筛选可用于预测房颤风险的标志物
(1)样本质控分析
以混合溶液作为QC样本,在仪器分析过程中,每隔10个检测分析样本插入一个质控样本,通过对同一质控样本质谱检测分析的总离子流图(TIC)进行重叠展示分析,如图1所示,代谢物检测总离子流的曲线重叠性高,即保留时间和峰强度均一致,表明质谱对同一样品不同时间检测时,信号稳定性较好。
对QC样本进行皮尔逊(Pearson)相关性分析,如图2所示,对角线方格代表QC样本名称;对角线左下角方格为对应QC样本相关性散点图,横纵坐标分别为代谢物含量,图中每个点代表一个代谢物;对角线右上角方格为对应QC样本相关性系数。QC样本相关性高( | r| 接近于 1 ),说明整个检测过程稳定性好,数据质量高。
CV值即变异系数(Coefficient of Variation),是原始数据标准差与原始数据平均数的比,可反映数据离散程度。使用经验累积分布函数(Empirical CumulativeDistribution Function, ECDF)分析对照组(SN)、实验组(SAF)和QC样本(QC)小于参考值的物质CV出现的频率,QC样本的CV值较低的物质占比越高,代表实验数据越稳定:QC样本CV值小于0.3的物质占比高于80%,表明实验数据稳定;QC样本CV值小于0.2的物质占比高于80%,表明实验数据非常稳定。结果见图3所示,横坐标代表CV值,纵坐标表示小于对应CV值的物质数目占总物质数的比例,不同颜色代表不同的分组样本,QC为质控样本,其中与X轴垂直的两条参考线对应的CV值为0.2和0.3,与X轴平行的参考线对应物质数目占总物质数的80%。结果显示,QC样本CV值小于0.2的物质占比高于80%,表明实验数据非常稳定。
(2)数据统计分析
对实验组数据、对照组数据和QC样本数据进行主成分分析(Principal ComponentAnalysis,PCA)以便初步了解各组样本之间的总体代谢差异和组内样本之间的变异度大小,进行正交偏最小二乘判别分析(OPLS-DA)以便寻找差异代谢物,OPLS-DA在原始数据进行log2转换后,再进行中心化处理(Mean Centering),然后利用R软件中的MetaboAnalystR 包 OPLSR.Anal 函数进行分析,根据OPLS-DA模型分析代谢组数据,绘制各分组的得分图,进一步展示各个分组之间的差异(Thévenot et al., 2015)。基于OPLS-DA模型的变量投影重要性(VIP)可以初步筛选出不同品种或组织间差异的代谢物。VIP值表示对应代谢物的组间差异在模型中各组样本分类判别中的影响强度,一般认为VIP ≥ 1的代谢物则为差异显著。同时结合单变量分析的P-value来进一步筛选出差异代谢物,获得造成患者和对照受试者的代谢谱扫描差异的代谢物。
结果显示,肌醇、油酸酰胺、1,3-二甲基尿酸、赖氨酸、4-羟基苯甲醛、3-羟基-5-胆甾烯酸酯、尿嘧啶、尿刊酸、邻苯二甲酸、原儿茶酸、鸟氨酸、乙酰谷酰胺、2-甲氧基苯甲酸、异胞嘧啶、N-乙酰-L-酪氨酸、2'-O-甲基胞苷、肌醇、L-亮氨酸、1,5-酐-D-山梨糖醇、精氨酸、甲硫氨酸的VIP ≥1,为差异代谢产物。
3、为了评估上述差异代谢物作为生物标志物的潜能,将获取的101例实验组人群数据及101例对照人群数据通过软件进行编辑,获得ROC(receiver operatorcharacteristic curve)曲线。
ROC曲线的绘制可以使用现有技术领域的软件或系统,比如SPSS 9.0、R0CP0WER.SAS、DESIGNR0C.FOR、R- studio等等。本实施例中绘制ROC曲线使用的软件R-studio。
ROC 曲线是反映真阳性率(灵敏度,又称敏感性,sensitivity)和假阳性率(特异性,specificity)连续变量的综合指标,是用构图法揭示灵敏度和特异性的相互关系。是以灵敏度为纵坐标、特异性为横坐标绘制的曲线,曲线下面积(AUC)越大,诊断准确性越高。
其中,对照人群和房颤人群的水平值均取中位数(第25百分位数,第75百分位数),以及单变量分析的p值,见下表所示。
参考值范围是对照人群通过大量人群实验检测后所得水平值取5-95%区间,见下表所示。
其中,表格显示参考值范围是第5百分位数(参考值下限)-第95百分位数(参考值上限)。
结果显示,10种代谢物均显示大于0.80的AUC,如图4-8所示,鸟氨酸、乙酰谷酰胺、尿嘧啶、2-甲氧基苯甲酸、N-乙酰-L-酪氨酸、肌醇、精氨酸、甲硫氨酸的水平在房颤患者中显著下降,AUC分别是0.951、0.913、0.953、0.899、0.822、0.8、0.896、0.815。异胞嘧啶和2'-O-甲基胞苷在房颤患者中显著上升,AUC分别是0.813和0.832。
组合1(即精氨酸、鸟氨酸、乙酰谷氨酸和甲硫氨酸的组合)的水平用于诊断心房颤动的准确性明显提高,AUC高达至0.96;
组合2(即鸟氨酸、乙酰谷酰胺、尿嘧啶、2-甲氧基苯甲酸、异胞嘧啶、N-乙酰-L-酪氨酸、2'-O-甲基胞苷、肌醇、尿刊酸、L-亮氨酸、1,5-酐-D-山梨糖醇和精氨酸的组合)以及组合3(即鸟氨酸、乙酰谷酰胺、尿嘧啶、2-甲氧基苯甲酸、异胞嘧啶、N-乙酰-L-酪氨酸、2'-O-甲基胞苷、肌醇、尿刊酸、L-亮氨酸、1,5-酐-D-山梨糖醇、精氨酸和甲硫氨酸的组合)的水平用于诊断心房颤动的准确性明显提高,AUC高达0.996和0.994(CL0.986-1.000)。
而其余代谢物单独预测的AUC均小于0.8,均未显示良好的预测能力。
实施例2 采用生物标志物预测心房颤动
心脏外科术后(冠状动脉旁路移植手术)病人3例,在术前按照实施例1的方法分别采集患者空腹状态下静脉血1ml,3000 rpm×10min 离心后留取上清于-80℃冻存,然后测试血清中精氨酸、鸟氨酸、乙酰谷氨酸、甲硫氨酸、尿嘧啶、2-甲氧基苯甲酸、异胞嘧啶、N-乙酰-L-酪氨酸、2'-O-甲基胞苷、肌醇、尿刊酸、L-亮氨酸和1,5-酐-D-山梨糖醇的水平。术前病例1提前进行药物干预,干预方法为:口服200mg制剂的胺碘酮(可达龙)一天两次,一次一片。病例2和3未进行药物干预。
其中,对于病例2来说,血清中鸟氨酸、乙酰谷酰胺、尿嘧啶、2-甲氧基苯甲酸、N-乙酰-L-酪氨酸、肌醇、异胞嘧啶、2'-O-甲基胞苷、精氨酸和甲硫氨酸等的水平均在对照人群的参考值范围内,预测不具有发生心房颤动的风险。经证实该病例心脏术后未发生房颤,预测结果与实际结果相一致。
病例3经检测鸟氨酸的水平低于参考值下限,预测具有发生心房颤动的风险,术前未进行药物干预,术后房颤持续时间较长,为36小时。
病例1经检测血清中精氨酸、鸟氨酸、乙酰谷氨酸、甲硫氨酸和肌醇的水平均低于参考值下限,预测具有发生心房颤动的风险,术前进行药物干预,术后房颤持续时间较短,为6小时。
由此说明,通过检测本发明所限定的生物标志物为心房颤动发生风险和预防提供有效信息,有利于实现对心脏外科术后心房颤动患者的预防性治疗,从而改善患者生存质量。
显然,上述实施例仅仅是为清楚地说明所作的举例,而并非对实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引伸出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
Claims (9)
1.一种生物标志物组合物在制备用于预测心房颤动发生风险的产品中的用途,其特征在于,所述生物标志物组合物包含精氨酸、鸟氨酸、乙酰谷酰胺和甲硫氨酸。
2.一种生物标志物组合物在制备用于预测心房颤动发生风险的产品中的用途,其特征在于,所述生物标志物组合物包含鸟氨酸、乙酰谷酰胺、尿嘧啶、2-甲氧基苯甲酸、异胞嘧啶、N-乙酰-L-酪氨酸、2'-O-甲基胞苷、肌醇、尿刊酸、L-亮氨酸、1,5-酐-D-山梨糖醇和精氨酸。
3.根据权利要求2所述的用途,其特征在于,所述生物标志物组合物还包含甲硫氨酸。
4.根据权利要求1-3中任一所述的用途,其特征在于,所述产品为试剂盒。
5.根据权利要求4所述的用途,其特征在于,所述试剂盒包括生物标志物的标准品。
6.根据权利要求1-3中任一所述的用途,其特征在于,所述预测是检测待测受试者血清或血浆中的生物标志物或者生物标志物组合物的水平值,若当受试者血清或血浆中权利要求1-3中任一所述的生物标志物组合物中的每一种生物标志物的水平值低于参考值下限或高于参考值上限时,则所述受试者具有发生心房颤动的风险。
7.根据权利要求6所述的用途,其特征在于,通过质谱联用液相色谱法测定生物标志物的水平。
8.根据权利要求1-3中任一所述的用途,其特征在于,所述心房颤动发生风险是指心脏外科手术术后发生心房颤动的风险。
9.权利要求1-3中任一所述的生物标志物组合物在筛选用于预防或治疗心房颤动的药物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211314441.XA CN115389756B (zh) | 2022-10-24 | 2022-10-24 | 一种预测房颤发生风险的检测试剂盒及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211314441.XA CN115389756B (zh) | 2022-10-24 | 2022-10-24 | 一种预测房颤发生风险的检测试剂盒及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115389756A CN115389756A (zh) | 2022-11-25 |
CN115389756B true CN115389756B (zh) | 2023-02-17 |
Family
ID=84128487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211314441.XA Active CN115389756B (zh) | 2022-10-24 | 2022-10-24 | 一种预测房颤发生风险的检测试剂盒及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115389756B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101160322A (zh) * | 2005-01-28 | 2008-04-09 | 阿波罗生命科学有限公司 | 分子及其嵌合分子 |
CN106483208A (zh) * | 2015-09-02 | 2017-03-08 | 实验室系统诊断有限公司 | 用于使用质谱法检测尿素循环障碍的新方法和试剂盒 |
CN109640962A (zh) * | 2016-05-18 | 2019-04-16 | 摩登纳特斯有限公司 | 编码松弛素的多核苷酸 |
CN112505228A (zh) * | 2021-01-04 | 2021-03-16 | 深圳市绘云生物科技有限公司 | 用于评估受试者心血管疾病风险的代谢标志物组合及其应用 |
CN113832223A (zh) * | 2021-09-24 | 2021-12-24 | 首都医科大学附属北京安贞医院 | 高血压血清细胞外囊泡蛋白标志物及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8608922B2 (en) * | 2008-11-07 | 2013-12-17 | The University Of Connecticut | Biosensor for continuous monitoring of metabolites and proteins and methods of manufacture thereof |
CN115112776B (zh) * | 2021-03-18 | 2023-07-04 | 中国科学院大连化学物理研究所 | 联合标志物及在诊断心房颤动中应用及诊断试剂或试剂盒 |
-
2022
- 2022-10-24 CN CN202211314441.XA patent/CN115389756B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101160322A (zh) * | 2005-01-28 | 2008-04-09 | 阿波罗生命科学有限公司 | 分子及其嵌合分子 |
CN106483208A (zh) * | 2015-09-02 | 2017-03-08 | 实验室系统诊断有限公司 | 用于使用质谱法检测尿素循环障碍的新方法和试剂盒 |
CN109640962A (zh) * | 2016-05-18 | 2019-04-16 | 摩登纳特斯有限公司 | 编码松弛素的多核苷酸 |
CN112505228A (zh) * | 2021-01-04 | 2021-03-16 | 深圳市绘云生物科技有限公司 | 用于评估受试者心血管疾病风险的代谢标志物组合及其应用 |
CN113832223A (zh) * | 2021-09-24 | 2021-12-24 | 首都医科大学附属北京安贞医院 | 高血压血清细胞外囊泡蛋白标志物及其应用 |
Non-Patent Citations (3)
Title |
---|
Targeting Amino Acids Metabolic Profile to Identify Novel Metabolic Characteristics in Atrial Fibrillation;Jiangqing She 等;《Clinical Science》;20181005;第132卷(第19期);第2135-2146页 * |
心力衰竭患者血浆代谢组学及新型生物标志物心脏特异性的研究;赵隽涵;《中国博士学位论文全文数据库——医药卫生科技辑》;20220215(第2期);第E062-73页 * |
心房颤动患者冠状静脉及左心房血浆非靶向代谢组学研究;李昊;《中国优秀硕士学位论文全文数据库——医药卫生科技辑》;20220215(第2期);第E062-279页 * |
Also Published As
Publication number | Publication date |
---|---|
CN115389756A (zh) | 2022-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Soldin et al. | Thyroid hormone testing by tandem mass spectrometry | |
Bajad et al. | Separation and quantitation of water soluble cellular metabolites by hydrophilic interaction chromatography-tandem mass spectrometry | |
Rashed | Clinical applications of tandem mass spectrometry: ten years of diagnosis and screening for inherited metabolic diseases | |
Soldin et al. | The measurement of free thyroxine by isotope dilution tandem mass spectrometry | |
JP2009528544A (ja) | 質量分析法を用いて異性体を識別するための方法 | |
Van Eijk et al. | Fully automated liquid-chromatographic determination of amino acids. | |
TWI553313B (zh) | 診斷心臟衰竭之方法 | |
Bohnstedt et al. | Determination of isoprostanes in urine samples from Alzheimer patients using porous graphitic carbon liquid chromatography–tandem mass spectrometry | |
Galla et al. | Simultaneous determination of 30 neurologically and metabolically important molecules: A sensitive and selective way to measure tyrosine and tryptophan pathway metabolites and other biomarkers in human serum and cerebrospinal fluid | |
CN112505228A (zh) | 用于评估受试者心血管疾病风险的代谢标志物组合及其应用 | |
EP3129909A1 (en) | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | |
Zhang et al. | Derivatization for the simultaneous LC/MS quantification of multiple neurotransmitters in extracellular fluid from rat brain microdialysis | |
Zhang et al. | Metabonomics study of urine and plasma in depression and excess fatigue rats by ultra fast liquid chromatography coupled with ion trap-time of flight mass spectrometry | |
Xiong et al. | DNA hydroxymethylation age of human blood determined by capillary hydrophilic-interaction liquid chromatography/mass spectrometry | |
Wijeyesekera et al. | Quantitative UPLC-MS/MS analysis of the gut microbial co-metabolites phenylacetylglutamine, 4-cresyl sulphate and hippurate in human urine: INTERMAP Study | |
Li et al. | Comparative analysis of nucleosides and nucleobases from different sections of Elaphuri Davidiani Cornu and Cervi Cornu by UHPLC–MS/MS | |
Vancea et al. | Determination of free captopril in human plasma by liquid chromatography with mass spectrometry detection | |
WO2023179804A1 (zh) | 一种利用超滤法换算平衡透析下游离物质含量的测定方法 | |
CN115389756B (zh) | 一种预测房颤发生风险的检测试剂盒及其应用 | |
Kasiari et al. | Selective and rapid liquid chromatography/negative-ion electrospray ionization mass spectrometry method for the quantification of valacyclovir and its metabolite in human plasma | |
Tsai et al. | Tandem derivatization combined with salting-out assisted liquid–liquid microextraction for determination of biothiols in urine by gas chromatography–mass spectrometry | |
Meng et al. | Broad targeted analysis of neurochemicals in rat serum using liquid chromatography tandem mass spectrometry with chemical derivatization | |
Lu et al. | High-performance liquid chromatography–mass spectrometric analysis of ramipril and its active metabolite ramiprilat in human serum: Application to a pharmacokinetic study in the Chinese volunteers | |
US20080311615A1 (en) | Method for chiral separation of lactic acid enantiomers | |
Kruglova et al. | Urine S-adenosylmethionine are related to degree of renal insufficiency in patients with chronic kidney disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240320 Address after: Room 401, 4th Floor, Building 56, Xinping North Road, Binhe Street, Pinggu District, Beijing, 101299 Patentee after: Beijing Century Hengkang Technology Co.,Ltd. Country or region after: Zhong Guo Address before: 100029 Beijing city Chaoyang District anzhen Road No. 2 Patentee before: BEIJING ANZHEN HOSPITAL AFFILIATED TO CAPITAL MEDICAL University Country or region before: Zhong Guo |